A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

Status:	Recruiting
Conditions:	Diabetes, Diabetes
Therapuetic Areas:	Endocrinology
Healthy:	No
Age Range:	18 - Any
Updated:	4/5/2019
Start Date:	December 20, 2018
End Date:	April 15, 2019
Contact:	There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Email:	clinicaltrials.gov@lilly.com
Phone:	1-317-615-4559

Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen

In this study participants will try out two different types of drug injection pens
(dulaglutide and semaglutide) on a practice pad and decide which device they prefer. No study
drug will be administered.

Inclusion Criteria:

- Diagnosed with type 2 diabetes

- Self-injection naïve to all injectable treatment (for example, diabetes therapies and
other medical conditions)

- Injection naïve to performing all injectable treatment (for example, diabetes
therapies and other medical conditions) to others

Exclusion Criteria:

- Currently diagnosed with gestational diabetes and/or type 1 diabetes

- Cognitive or physical difficulties that could interfere with ability to understand the
training, perform the injection tasks, or complete the study questionnaires as judged
by the investigator

- Is a health care practitioner who is trained in giving injections

We found this trial at

sites

BRCR Medical Center, Inc.

Camp Hill, Pennsylvania 17011

Principal Investigator: Kaushal R Patel

Phone: 208-346-8900

from

Camp Hill, PA